Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study

NCT05256017 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.

NCT NCT05256017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Non-parasitologically Confirmed Subjects: a Multicentre Randomised Double-blind Placebo-controlled Study
Lead sponsor
Drugs for Neglected Diseases
Phase
Phase 2/3
Overall status
Completed
Start date
December 30, 2021
Completion date
August 3, 2023
Enrollment
1,208 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

sleeping sickness, trypanosoma brucei gambiense; infection, trypanosomiasis, african